Institute for Rare and Neglected Diseases Drug Discovery
- Research works
- 13 ▼ 96% vs 2013–17
- Citations
- 743 56.9 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 48% world 28%
Not ranked overall: Institute for Rare and Neglected Diseases Drug Discovery is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which research topics does Institute for Rare and Neglected Diseases Drug Discovery publish most on?
By volume in 2022–2025: Pharmaceutical Economics and Policy, Tuberculosis Research and Epidemiology and HIV/AIDS drug development and treatment.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Pharmaceutical Economics and Policy Economics and Econometrics 0 works
- 2 Tuberculosis Research and Epidemiology Infectious Diseases 0 works
- 3 HIV/AIDS drug development and treatment Infectious Diseases 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Institute for Rare and Neglected Diseases Drug Discovery's research output changed?
Output in 2018–2022 was 96% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Mountain View
- Ames Research Center
- Google (United States)
- Creative Commons
- Synopsys (United States)
- Search for Extraterrestrial Intelligence
- Khan Academy
- Intuit (United States)
- Research Institute for Advanced Computer Science
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.